Abstract
Cardiac homeostasis relies on the appropriate provision of nutrients to the working myocardium. EPHB4 is required for the maintenance of vascular integrity and correct fatty acid transport uptake in the heart via regulating the caveolar trafficking of the fatty acid receptor CD36. In the mouse, endothelial specific loss-of-function of the receptor EphB4, or its ligand ephrin-B2, induces Dilated Cardiomyopathy (DCM) like defects. Now, we have identified six new EPHB4 variants with deleterious potential in a cohort of 573 DCM patients. Similar to the EphB4 mutant mice, EPHB4 variants carrying patients show an altered expression pattern of CD36 and CAV1 in the heart. For the first time, our data identifies EPHB4 mutations in DCM patients. This observation supports the notion that the Eph-ephrin signalling pathway, and in particular the receptor EPHB4, plays a role in the development of DCM in human patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the German Centre for Cardiovascular Research (DZHK). Grant UA.0004.21 to G.L.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institute for Cardiomyopathies Heidelberg (ICH): Ethical approval has been obtained from the local ethics committee (University of Heidelberg, S-344/2014). TORCH-Plus-DZHK: Ethical approval has been obtained from the leading ethics committee (University of Heidelberg, S-344/2014) and subsequently from all responsible ethics committees of the participating centers involved. ClinicalTrials.gov Identifier: NCT02187263. DRKS-ID (Deutsches Register Klinischer Studien): DRKS00008017. The single-nucleus-RNA-sequencing data set generated in the paper by Nicin et al. (Nicin et al., 2022) (https://www.nature.com/articles/s44161-022-00019-7#Sec9) was used to explore EPHB4 expression in human cardiac cells
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The discussion of the manuscript has been revised to clarify the findings of the work.
